Pages
- Accueil
- All events
- Board of Directors
- Commercial Manufacturing
- Company
- Confidentiality policy
- Contact & quotation request
- Contact the personal data protection officer
- Cosmetic peptides
- COVID-19 Information
- Custom R&D
- Generic peptides
- Individualized Peptides
- Investors
- New Products
- News
- Newsletter
- Oligo
- Oligos
- Personal data
- Quality at PolyPeptide
- Request our Documentation
- Scale and Synthesis strategy
- Search Result
- Services
- Subscribe to PolyPeptide Newsletter
- Board of Directors
- Board of Directors
- Board of Directors
- Board of Directors
- Board of Directors
- Contacts
- Executive Committee
- Executive Committee
- Executive Committee
- Executive Committee
Posts by category
- Category: Ad hoc announcements pursuant to Art. 53 LR
- CEO of PolyPeptide resigns
- PolyPeptide signs significant commercial agreement
- PolyPeptide provides market update
- PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
- PolyPeptide provides market update
- PolyPeptide achieves strong profitable growth in 2021
- PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen
- Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG
- PolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends
- PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee
- PolyPeptide Group announces the exercise of the full over-allotment option
- Category: Media releases
- Monika Casanova joining PolyPeptide as CHRO and member of the PMC
- PolyPeptide announces results of the annual General Meeting 2022
- PolyPeptide publishes invitation to the annual General Meeting 2022
- PolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients
- PolyPeptide Group appoints Raymond De Vré as new Chief Executive Officer
- PolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine
- Category: Business news
- FluoGuide reaches milestone with FG001 for phase III clinical supply
- PolyPeptide wins Malmö Life Science Business Award
- Efficient and sustainable solutions for large scale peptide manufacturing
- Proclamation honoring Jane Salik upon her retirement
- Stock exchange listing
- PolyPeptide News Flash, #1, 2021
- Therapeutic indications for the PolyPeptide Group pipeline projects 2020
- New in-silico development tools support more efficient process design
- PolyPeptide News Flash, #3, 2020
- Capacity Expansion through Investment and Innovation
- PolyPeptide News Flash, #2, 2020
- Information Letter on COVID-19
- New member of the Medicon Valley Alliance
- PolyPeptide News Flash February 2020
- Innovation and Technology
- PolyPeptide News Flash October
- Press release: the start of a research collaboration program with IBMM in Montpellier, France
- Symposium on Preparative and Process Scale HPLC, MCC and SFC 2019
- Book your meeting with PolyPeptide at CPhI worldwide – Frankfurt, Germany 5-7 November 2019
- 100% sustainable energy from wind turbines at PolyPeptide Sweden
- PolyPeptide attends TIDES Europe – Amsterdam, November 7th and 8th
- Category: Expert views
- From 10 grams to several hundred – A case study in peptide GMP process development
- Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Environmentally Sensible Organocatalytic Fmoc/t Bu Solid-Phase Peptide Synthesis
- SPPS: Process improvements to reduce solvent consumption
- Circular Aqueous Fmoc/t-Bu Solid-Phase Peptide Synthesis
- Downstream Processes for peptide manufacturing: Optimization strategy and latest technical trends
- Green Chemistry Articles of Interest to the Pharmaceutical Industry
- Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions
- Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions
- Selection of publications on significant advances in production and use of Peptides
- Sustainable, cost-efficient manufacturing of therapeutic peptides using chemo-enzymatic peptide synthesis (CEPS)
- QA interview: Focus innovation
- ReGreen SPPS: enabling circular chemistry in environmentally sensible solid-phase peptide synthesis
- Economic and environmental factors affecting the sustainability of peptide therapeutic manufacturing
- A Holistic Quality Control Strategy for Peptide Active Pharmaceutical Ingredients (APIs)
- Poster: Benzylthiols as scavengers in TFA cleavages of peptide resins
- 2D green SPPS: green solvents for on-resin removal of acid sensitive protecting groups and lactamization
- Panel discussion on peptides
- Aspects of greening peptide chemistry within the pharmaceutical manufacturing industry
- Panel discussion on pharma and chemical supply chain
- Advanced SPPS
- Needle-to-needle’: Manufacturing NeoAntigen peptides
- Poster: Towards cost-efficient, scalable green SPPS
- 1,4-Benzenedimethanethiol (1,4-BDMT) as a scavenger for greener peptide resin cleavages
- Suitable solvent for cost-efficient green SPPS
- Considerations for multi-product manufacturing facilities
- Designing quality into therapeutic peptide manufacturing
- Process validation: Manufacturing peptide APIs
- Control strategies for synthetic therapeutic peptide APIs – Part III: Manufacturing process considerations
- Control strategies for synthetic therapeutic peptide APIs – Part II: Raw material considerations
- Control strategies for synthetic therapeutic peptide APIs – Part I: Analytical consideration
- The ideal peptide plant
- Meeting the growing demand for peptide therapeutics
- Bioconjugates: The adaptable challenge
- Poster: Focus on Controlling Non-peptide Impurities in Peptide API Manufacturing
- Challenges in technology transfers of API manufacturing to India
- Challenges for therapeutic peptides part 2: Delivery systems
- Challenges for therapeutic peptides Part 1: On the inside, looking out
- Building global QA system and compliance
- DTT reacts with TFA to form a novel bicyclic dithioorthoester
- Quality by design, a peptide CMO approach
- The future of peptide development in the pharmaceutical industry
- Building business in therapeutic peptides
- Are low-priced peptides affordable?
- A peptide specialist
- Quality control in peptide manufacturing: specifications for GMP peptides
- Aspects of industrial purification of peptides using large scale chromatography
- Large-Scale synthesis of peptides
Generic peptides
- Semaglutide
- Triptorelin
- Somatostatin
- PTH (1-34) Teriparatide
- Octreotide
- Liraglutide
- Leuprolide
- Felypressin
- Desmopressin
- Deslorelin
- Calcitonin
- Atosiban
- Vasopressin, 8-L-Arginine
- Exenatide
- Carbetocin
- ACTH (1-39) Porcine
Events
- Biologics UK
- Bioscience Talent Connections, Career Fair
- KULA
- In-cosmetics global
- HubXchanges
- BIO Europe Spring
- DCAT week
- RNA leaders Europe
- Asia TIDES
- RNA Therapeutics
- Half year results 2024
- General Meeting 2024
- Full year results 2023
- Half year results 2023
- Market Update with Audio Webcast and Conference Call
- HubXchange - Oligonucleotides
- Biotech Showcase
- Baader Helvea Swiss Equities Conference
- Octavian Swiss Seminar
- ARKAD
- Berenberg European Conference
- Credit Suisse Equity Forum Switzerland 2022
- Jefferies Healthcare Conference
- ZKB Swiss Equities Conference 2022
- RNA leaders
- TIDES Europe
- EPS 2022
- CPhI Worldwide Europe
- Nordic Life Science - NLS days
- Boulder Peptide Symposium
- Demo event
- Demo event
- Demo event
- Half year results conference 2022 at 09:30am
- European Peptide Symposium
- IOPC: International Oligonucleotides and Peptides Conference
- BIO International Convention
- Full year results 2022
- Baader Swiss Equities Conference, digital
- Octavian Seminar, Flims, CH
- FY 2021 Results
- FY2021 Results conference
- Last trading day incl. dividend entitlement
- Dividend ex-date
- Dividend record date
- Dividend payment date
- Half year results 2022 at 07:00am
- 2021 Half-Year Results
- Morgan Stanley 19th Annual Global Healthcare Conference
- ZKB Swiss Equities Conference
- 14th Credit Suisse Equity Forum Switzerland
- Berenberg Swiss Seminar, digital
- General Meeting 2023
- General Meeting 2022